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 Lung cancer is a leading cause of death in industrialized countries 
and accounts for 20% of all cancer deaths. Modifications in smok-
ing habits and in the tar and nicotine composition of cigarettes 
have led to changes in the distribution of histologic subtypes. 
Adenocarcinoma is now the most common type of lung cancer; 
squamous cell carcinoma and small cell lung cancer (SCLC) have 
decreased during the past 20 years ( 1 – 3 ). SCLC accounted for 25% 
of all lung cancers in the United States in the 1990s but only 12.9% 
in 2002 ( 2 , 4 ). The number of patients who are diagnosed with lung 
cancer has also decreased in some European countries but has con-
tinued to increase in others ( 2 ) and remains at 25  000 – 50  000 people 
per year in Europe ( 5 , 6 ). 
 Chemotherapy has dramatically improved the prognosis of 
SCLC patients, but the recurrence rate after chemotherapy is still 
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 ARTICLE 
 A Threefold Dose Intensity Treatment With 
Ifosfamide, Carboplatin, and Etoposide for Patients 
With Small Cell Lung Cancer: A Randomized Trial 
 Serge  Leyvraz ,  Sandro  Pampallona ,  Giovanni  Martinelli ,  Ferdinand  Ploner ,  Lucien  Perey ,  Savina  Aversa , 
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  Background  The dose intensity of chemotherapy can be increased to the highest possible level by early administration 
of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor 
cells (PBPCs). A randomized trial was performed to test the impact of such dose intensification on the 
long-term survival of patients with small cell lung cancer (SCLC). 
  Methods  Patients who had limited or extensive SCLC with no more than two metastatic sites were randomly 
assigned to high-dose (High, n = 69) or standard-dose (Std, n = 71) chemotherapy with ifosfamide, carbo-
platin, and etoposide (ICE). High-ICE cycles were supported by transfusion with PBPCs that were collected 
after two cycles of treatment with epidoxorubicin at 150 mg/m 2 , paclitaxel at 175 mg/m 2 , and filgrastim. 
The primary outcome was 3-year survival. Comparisons between response rates and toxic effects within 
subgroups (limited or extensive disease, liver metastases or no liver metastases, Eastern Cooperative 
Oncology Group performance status of 0 or 1, normal or abnormal lactate dehydrogenase levels) were 
also performed. 
  Results  Median relative dose intensity in the High-ICE arm was 293% (range = 174% – 392%) of that in the Std-ICE 
arm. The 3-year survival rates were 18% (95% confidence interval [CI] = 10% to 29%) and 19% (95% CI = 
11% to 30%) in the High-ICE and Std-ICE arms, respectively. No differences were observed between the 
High-ICE and Std-ICE arms in overall response (n = 54 [78%, 95% CI = 67% to 87%] and n = 48 [68%, 95% 
CI = 55% to 78%], respectively) or complete response (n = 27 [39%, 95% CI = 28% to 52%] and n = 24 [34%, 
95% CI = 23% to 46%], respectively). Subgroup analyses showed no benefit for any outcome from High-
ICE treatment. Hematologic toxicity was substantial in the Std-ICE arm (grade  ≥ 3 neutropenia, n = 49 
[70%]; anemia, n = 17 [25%]; thrombopenia, n = 17 [25%]), and three patients (4%) died from toxicity. High-
ICE treatment was predictably associated with severe myelosuppression, and five patients (8%) died from 
toxicity. 
  Conclusions  The long-term outcome of SCLC was not improved by raising the dose intensity of ICE chemotherapy by 
threefold. 
  J Natl Cancer Inst 2008;100: 533 – 541 
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 CONTEXT AND CAVEATS 
 Prior knowledge 
 Most small cell lung cancers (SCLCs) recur and become resistant to 
chemotherapy. 
 Study design 
 Randomized trial to compare high-dose (High) with standard-dose 
(Std) ifosfamide, carboplatin, and etoposide (ICE) in SCLC patients 
with limited or extensive disease. 
 Contributions 
 The treatment intensity in the High-ICE arm was almost three times 
that in the Std-ICE arm. No differences between the two groups in 
3-year survival or in overall or complete response were observed. 
Both treatments induced severe toxicities. 
 Implications 
 Long-term outcome of SCLC was not improved by increasing ICE 
treatment intensity nearly threefold, and toxicities were severe. 
Thus, intense ICE therapy for SCLC should not be used in the 
future. 
 Limitations 
 The study had low accrual, and the initial trial design had to be 
altered to include interim analyses.  
high. Indeed, patients with limited disease can expect to live for a 
median of only 12 – 20 months after diagnosis and those with exten-
sive disease only 8 – 10 months. Only 10% of patients with limited 
disease survive for 5 years ( 4 , 7 – 8 ). Despite initial response to che-
motherapy, tumors recur in the majority of patients in less than a 
year and are then highly resistant to further therapy . 
 Various approaches to improve the efﬁ cacy of chemotherapy and 
to overcome chemoresistance of SCLC have been explored by test-
ing novel agents, new combination regimens, and different sched-
ules. Regimens that contain cisplatin are used most commonly and 
have been demonstrated by meta-analysis to yield a survival beneﬁ t 
over regimens that lack cisplatin ( 9 ). The etoposide /cisplatin (PE) 
regimen is a widely accepted standard ( 10 ). Indications of better 
outcomes with irinotecan instead of etoposide ( 11 ) have not been 
conﬁ rmed by recent evidence ( 12 ). The addition of paclitaxel to PE 
increases toxicity but does not improve response rates or median 
survival ( 13 , 14 ). Other investigators have incorporated ifosfamide in 
regimens known as ICE (ifosfamide, carboplatin, and etoposide) 
and VIP (cisplatin, ifosfamide, and etoposide). Randomized studies 
with these regimens have suggested statistically signiﬁ cant beneﬁ ts 
in progression-free and overall survival compared with standard PE 
or cyclophosphamide, doxorubicin, and vincristine (CAV) regimens 
( 15 , 16 ). The ICE regimen, which avoids the nephrotoxicity, ototox-
icity, and neurotoxicity of cisplatin, has been tested extensively for 
the treatment of SCLC, mainly in European institutions ( 17 – 19 ). 
However, it has not been widely accepted because ICE is more toxic 
than PE and cannot be given concurrently with radiotherapy. 
 Given its high chemosensitivity but early appearance of chemo-
resistance, we deemed SCLC suitable for attempting to maximize 
the chemotherapy dose level per cycle, the total dose, or the dose 
intensity. This strategy was supported by experimental data 
obtained in vitro, suggesting that drug concentrations had to be 
increased threefold to ﬁ vefold to obtain a similar level of cell lysis 
in resistant SCLC cell lines as in sensitive ones ( 20 ). The high-
dose ICE combination (High-ICE) has been tested in different 
tumor types ( 21 , 22 ) and has a known toxicity proﬁ le (myelosup-
pression) that can be controlled by support with peripheral blood 
progenitor cells (PBPCs). Furthermore, the European Group for 
Blood and Marrow Transplantation (EBMT) has previously tested 
administration of High-ICE in multiple and sequential cycles in 
patients with SCLC supported by the transfusion of PBPCs ( 23 ). 
We carried out a trial to compare standard-dose ICE (Std-ICE) 
with repeated High-ICE treatment administered to SCLC patients 
with a relatively good prognosis who might beneﬁ t from such 
a very intensive strategy. The main objectives were to double the 
3-year survival rate, to compare response rates and toxicity, and to 
deﬁ ne the impact on different patient subgroups. 
 Subjects and Methods 
 Patient Selection 
 Eligible patients had previously untreated, histologically con-
firmed SCLC. Participating centers had to be members of the 
EBMT. Disease staging was determined by clinical examination; 
chest, abdominal, and brain computed tomography (CT) scan; 
bone scan; and bone marrow biopsy  and aspiration . Patients were 
included if they had limited disease (no metastases outside the 
thorax) or extensive disease with two or fewer metastatic sites, 
excluding brain; were 65 years old or younger; had an Eastern 
Cooperative Oncology Group (ECOG) performance status of 0 or 
1; had no previous treatment; had normal hematologic, renal, and 
cardiac function; and had liver function tests within 2.5 times the 
normal range (the standard for patients with potential liver metas-
tases to have adequate liver function to tolerate chemotherapy). 
 Study Design 
 The trial was a phase III two-arm open-label trial, with centralized 
randomization by the minimization method (stratification factors: 
limited disease extent, extensive without liver metastases, and 
extensive with liver metastases; ECOG performance status of 0 or 
1; and normal or elevated levels of lactate dehydrogenase [accord-
ing to the laboratory upper normal values of each center]). Random 
allocation was with center override to avoid imbalances of more 
than three patients between the two arms. All patients provided 
written informed consent, and the trial was approved by each 
institution’s Institutional Review Board. Trial registration: EU-
98001, NCI-V-1645, NCT00011921. 
 High-Dose Chemotherapy with Ifosfamide, Carboplatin, 
and Etoposide Arm 
 Every 28 days, patients were intravenously administered three cycles 
of ifosfamide at 2.5 g/m 2 per day × 4 days (10 g/m 2 ), carboplatin at 
area under the curve (AUC) = 5.0 per day × 4 days (AUC = 20), eto-
poside at 300 mg/m 2 per day × 4 days (1200 mg/m 2 ), and uromitexan 
at 5.0 g/m 2 per day on days 1 – 5 ( 23 ). PBPCs ( ≥ 2 × 10 6 CD34+ cells 
per kg) that had been collected before ICE treatment began (see 
below) were reinfused 48 hours after chemotherapy, and filgrastim 
at 5  µ g/kg per day was administered subcutaneously for 14 days. 
 Treatment cycles were delayed up to 2 weeks until leukocyte 
concentrations recovered to 3.5 × 10 9 /L or greater, granulocyte 
jnci.oxfordjournals.org   JNCI | Articles 535
concentrations recovered to 1 × 10 9 /L or greater, and platelet 
concentrations recovered to 100 × 10 9 /L or greater. Etoposide 
dose was reduced by 30% in patients with World Health 
Organization (WHO) grade 3 or greater esophagitis, mucositis, or 
diarrhea. Carboplatin was omitted if grade 3 or greater neuropathy 
was present. Ifosfamide treatment was omitted in  the presence of 
central nervous system toxicity (WHO grade  ≥ 3 ) ( 24 ). 
 Collection of Peripheral Blood Progenitor Cells 
 Patients in the High-ICE arm only had PBPCs reinfused after each 
of the three ICE cycles to limit the magnitude of myelosuppression 
induced by the high treatment intensity. Six to eight weeks before 
patients were given ICE treatment, they were given two cycles of 
non – cross-resistant chemotherapy (ie, paclitaxel and epidoxorubicin) 
with the intent to purge circulating tumor cells in vivo ( 25 ). A 4-hour 
infusion of epidoxorubicin at 150 mg/m 2 was given on day 1, and a 3-
hour infusion of paclitaxel at 175 mg/m 2 was given on day 2; both were 
repeated after 21 days. After the second cycle, filgras tim at 5  µ g/kg was 
delivered until PBPC collection was completed. CD34    cells [9 × 10 6 
per kg, as measured by flow cytometry ( 26 )] were collected to support 
the three cycles of ICE treatment, and low counts at leukapheresis 
(<6 × 10 6 per kg) were regarded as treatment failure. Leukapheresis 
was repeated daily until adequate numbers of PBPCs were obtained. 
 Standard-Dose Chemotherapy with Ifosfamide, 
Carboplatin, and Etoposide Arm 
 Patients received six cycles (28 days per cycle) of ifosfamide at 
5.0 g/m 2 and carboplatin at 300 mg/m 2 intravenously on day 1, etopo -
side at 180 mg/m 2 intravenously on days 1 and 2, and uromitexan at 
5.0 g/m 2 on days 1 and 2 ( 27 ). No dose reduction was permitted. 
Chemotherapy was delayed up to 2 weeks in the presence of non-
hematologic toxicity grade 3 or greater (except nausea, diarrhea, or 
alopecia) and if creatinine clearance was less than 50 mL/min, leu-
kocyte concentrations were less than 3 × 10 9 /L, and platelet concen-
trations were less than 30 × 10 9 /L. 
 Ifosfamide, Carboplatin, and Etoposide Dose Intensity 
 Relative dose intensity (total dose received over actual treatment 
duration divided by total dose prescribed by the protocol over the 
theoretic treatment period) was calculated as described by Lorigan 
et al. ( 28 ) with the duration for the last treatment cycle set to 28 
days. Median relative dose intensity was calculated for each treat-
ment cycle for all patients. As a measure of relative dose intensifi-
cation, relative dose intensity was also computed for patients in the 
High-ICE arm with reference to the Std-ICE protocol. 
 Radiotherapy 
 After the end of chemotherapy, when all toxicities had resolved, 
thoracic radiotherapy at a total dose of 60 Gy in 2-Gy fractions was 
proposed for patients who had responding limited disease and those 
who had extensive disease in complete remission. Patients in com-
plete remission were also offered prophylactic cranial irradiation 
(PCI) at a dose of 30 Gy. 
 Assessment of Toxicity and Treatment Response 
 Examinations During Chemotherapy.  Clinical examinations were 
performed weekly. Complete blood counts were obtained twice 
weekly using standard methods. Each treatment cycle was preceded 
by hepatic and renal function tests (transaminases, gammaglutamyl-
transphosphatase, alkaline phosphatase) using standard methods and 
chest radiography. Toxicity was graded according to WHO criteria 
( 24 ). 
 Examinations After Chemotherapy/Radiotherapy.  The follow-
ing were performed after all cycles of chemotherapy were com-
pleted: physical examination; chest radiography; CT scan of the 
chest and abdomen; bronchoscopy, including biopsy; cardiac left 
ventricular ejection fraction (multiple-gated acquisition scan or 
echocardiography); bone scan if initially positive; bilateral bone 
marrow biopsy; complete blood count; biochemical profile; and 
renal function test. A CT scan of the chest was also performed in 
all patients at the end of thoracic radiotherapy. 
 Examinations During Follow-up.  Comprehensive medical histo-
ries, clinical examinations, and complete blood counts were obtained 
every month. Biochemical profiles, renal function tests, and chest 
radiography were performed every 3 months. CT scans of the chest 
and abdomen were obtained at minimum intervals of 6 months. 
 Response Criteria.  Each patient’s total tumor load was established 
by summing bidimensional tumor measurements that were obtained 
from CT scan, in which the longest diameter of each lesion was 
multiplied by its perpendicular diameter. Response to treatment 
was classified in accordance with modified WHO criteria ( 29 ). 
 Statistical Analysis 
 The primary endpoint was overall  survival based on time from 
random assignment to death. Secondary endpoints included 1) 
progression-free survival based on time from random assignment 
to death or disease progression (local or metastatic), whichever 
occurred first; 2) overall response rate; and 3) toxicity. Percentages 
of events over time were calculated with the Kaplan – Meier method 
( 30 ). Greenwood’s formula ( 31 ) was applied to obtain the corre-
sponding standard errors. Each comparison of survival results is 
presented with  P values from the log-rank test ( 32 ). Response rates 
and other percentages were compared with the   2 test. All proba-
bility values are from two-sided tests, and  P values less than .05 
were considered to be statistically significant. All analyses were 
performed according to the intention-to-treat principle, after the 
exclusion of five patients (see “Results”). Exploratory subgroup 
analyses were performed according to sex and to the factors used to 
stratify randomization (see above, “Study Design”). Patients who 
were lost to follow-up or refused treatment were not excluded from 
the analysis. An independent data monitoring committee (IDMC) 
was set up to review toxic events and to issue recommendations for 
continuation or modification of the study. 
 It was expected that High-ICE treatment would raise the 
3-year survival from 12% to 24%. A power of 90%, a statistical 
signiﬁ cance level of 5%, 3 years of accrual, and 1 year of follow-up 
were considered; thus, the study required 270 deaths for 360 
patients accrued ( 33 ). The study began accruing patients in 1997, 
but the accrual rate was much lower than expected, and in 2004, it 
was agreed with the IDMC to convert the original ﬁ xed sample 
design to a sequential design with three equally spaced interim 
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analyses. The maximum number of events was adjusted to 311 due 
to the introduction of the stopping rule. The latter was based on 
boundaries for early stopping in favor of a difference (O’Brien –
 Fleming error spending function) or of lack thereof (Pocock 
Fleming error spending function) ( 33 ). At the time of the ﬁ rst 
interim analysis, the boundaries for early stopping with 114 events 
corresponded to type I and II error probabilities of 0.0004267 and 
0.0488374, respectively. The following decision rule applied: stop 
in favor of the null hypothesis of no treatment difference if the 
log-rank test statistic is in the range of   0.500 to 0.500, stop in 
favor of the alternative hypothesis if this statistic is smaller than 
  3.523 or larger than 3.523, otherwise continue the trial. 
 Results 
 Patient Characteristics 
 A total of 145 patients from 18 centers were randomly assigned 
between June 19, 1997, and December 20, 2005, to High-ICE (n = 74) 
or Std-ICE (n = 71). Four patients in the High-ICE arm never started 
protocol treatment because they were identified as being clearly ineli-
gible for the study after random assignment and were therefore 
excluded from all analyses (two had brain metastases, one had low 
ejection fraction, and one had acute coronary syndrome). One addi-
tional patient in the High-ICE arm was excluded from the analyses 
because the center never provided any data ( Table 1 ). Baseline charac-
teristics ( Table 2 ) were well balanced across the treatment arms. 
 Peripheral Blood Progenitor Cell Mobilization and 
Collection 
 PBPCs were mobilized in all 69 patients in the High-ICE arm, but 
leukapheresis was not performed in four patients (toxic death, n = 2 
[see below]; disease progression, n = 1; refusal, n = 1). A median of 
16.7 (range = 7 – 52) × 10 6 CD34    cells per kg were obtained after 
one, two, or three or more rounds of leukapheresis in 27 patients, 
27 patients, and 11 patients, respectively. 
 Toxicity during mobilization consisted of neutropenia and 
reached grade 3/4  in 41 (59%) patients, with severe infections in 4 
(6%). Two toxic deaths occurred related to sepsis (n = 1) and 
severe lysis syndrome (n = 1). Other toxicities included grade 3/4 
thrombocytopenia in seven patients (10%), grade 3/4 anemia in 
ﬁ ve patients (7%), mucositis in six patients (9%), and severe nausea 
in four patients (6%). 
 Treatment Cycles 
 High-Dose Chemotherapy With Ifosfamide, Carboplatin, and 
Etoposide Arm.  Eight of the 69 patients never started chemo-
therapy (refusal, n = 2; tumor progression, n = 3; toxic death, n = 
2; preexisting clotting disorder, n = 1). A total of 43 patients (62%) 
underwent the entire course of three sequential cycles. Reasons 
for not completing all three treatment cycles included refusal 
 Table 1 .  CONSORT flowchart of the trial * 
 Category
No. in each trial 
arm (N = 145) 
 High-ICE Std-ICE 
 Allocated to intervention 74 71 
 Received allocated intervention 69 71 
 Did not receive allocated intervention 5 0 
  Reasons  
  Ineligible 4 0 
  Absence of data 1 0 
 Lost to follow-up but analyzed 0 1 
 Chemotherapy was discontinued 26 19 
  Reasons  
  Toxic death during mobilization 2 0 
  Progression during mobilization 3 0 
  Refusal 5 3 
  Toxicity 9 2 
  Progression 1 10 
  Clinically indicated 1 2 
  Insufficient PBPC collection 1 0 
  Toxic death 4 2 
 Completed all cycles 43 52 
 Analyzed for efficacy and toxicity 69 71 
 *  High = high-dose; Std = standard-dose; ICE = ifosfamide, carboplatin, and 
etoposide; PBPC = peripheral blood progenitor cells. 
 Table 2 .  Patient characteristics * 
 Characteristic High-ICE (n = 69) Std-ICE (n = 71) Total (N = 140) 
 Disease extent, No. 
  Limited disease 49 48 97 
  Extensive without liver involvement 14 16 30 
  Extensive with liver involvement 6 7 13 
 Sex, No. 
  Male 52 51 103 
  Female 17 20 37 
 LDH concentration at registration, No. 
  Normal 45 45 90 
  Elevated 24 26 50 
 ECOG performance status, No. 
  0 41 41 82 
  1 28 30 58 
 Age, mean (range), y 52 (31 – 68) 54 (33 – 66) 53 (31 – 68) 
 Weight loss, mean (range), kg 2.5 (0 – 16) 2.1 (0 – 12) 2.3 (0 – 16) 
 *  High = high-dose; Std = standard-dose; ICE = ifosfamide, carboplatin, and etoposide; LDH = lactate dehydrogenase; ECOG = Eastern Cooperative Oncology 
Group; limited disease = disease restricted to the ipsilateral hemithorax that can be encompassed within a radiation treatment plan. Elevated LDH values are 
defined as greater than the upper normal value given by the laboratory of each participating center. 
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(n = 3), toxicity (n = 9), toxic death (n = 4), progression (n = 1), and 
insufficient stem (CD34+) cells (n = 1). A total of 158 cycles were 
administered overall. Transfusion with PBPCs was applied with 
a median 5.1 (range = 2.1 – 12.7) × 10 6 CD34    cells per kg per 
cycle. 
 Standard-Dose Chemotherapy With Ifosfamide, Carboplatin, 
and Etoposide Arm.  One of the 71 patients died before chemo-
therapy was begun. A total of 52 patients (73%) underwent the 
entire treatment course of six cycles. Reasons for not completing 
all six cycles included refusal (n = 3), toxicity (n = 2), toxic death 
(n = 2), disease progression (n = 8), tumor-related death (n = 2), and 
discontinuation for clinical reasons (n = 2). A total of 365 cycles 
were administered overall. 
 Dose Intensity 
 Compliance with the treatment plan was good. Compared with the 
dose levels that were defined in the protocol, the median dose 
intensities administered reached 91% (range = 90% – 97%) in the 
High-ICE arm and 99% (range = 99% – 100%) in the Std-ICE arm. 
Median relative dose intensification for patients in the High-ICE 
arm compared with that in patients in the Std-ICE arm was 293%, 
with a range of 174% – 392%. 
 Toxicity 
 Toxic events were mainly hematologic in nature. In the Std-ICE 
arm, grade 3/4 leukopenia was observed in 49 patients (70%). A 
total of 17 patients (25%) in this arm exhibited grade 3/4 throm-
bocytopenia and anemia. In the Std-ICE arm, grade 3/4 infections 
occurred in four (6%) patients and toxic deaths occurred in three 
patients (4%). In the High-ICE arm, all 61 patients exhibited 
grade 4 leukopenia and thrombocytopenia and 54 patients (88%) 
had grade 3/4 anemia. Grade 3/4 infections affected 19 (31%) 
patients in the High-ICE arm, and five (8%) toxic deaths 
occurred. Other toxicities (eg, nausea and vomiting, diarrhea, 
mucositis, renal, neurological) were more prevalent and severe in 
the High-ICE arm than the Std-ICE arm ( Table 3 ). Patients in 
the High-ICE arm remained hospitalized for a median of 19.6 
(range = 8 – 91) days vs 4.3 (0 – 32) days for patients in the Std-ICE 
arm. 
 Response to Treatment 
 The response rates are based on the entire sample of 140 patients. 
Antitumor responses were observed in 54 of 69 patients in the 
High-ICE arm and 48 of 71 patients in the Std-CE arm. These 
rates (78%, 95% confidence interval [CI] = 67% to 87%, and 68%, 
95% CI = 55% to 78%) were not statistically significantly different 
( P = .156). The number of complete responders was 27 (39%, 95% 
CI = 28% to 52%) in the High-ICE arm and 24 (34%, 95% CI = 
23% to 46%) in the Std-ICE arm. Response rates were also not 
different between the two arms when looking at disease extension 
subgroups. Among patients with limited disease, overall response 
(complete plus partial reponses) was seen in 39 of 49 patients (80%, 
95% CI = 66% to 90%) and 33 of 48 patients (69%, 95% CI = 54% 
to 81%) ( P = .25) in the High- and Std-ICE arms, respectively. 
Similarly, among patients with extensive disease, the proportions 
were 15 of 20 (75%, 95% CI = 51% to 91%) and 15 of 23 (65%, 
95% CI = 43% to 84%) ( P = .49), respectively. 
 Radiotherapy 
 Forty-four patients in the High-ICE arm and 48 in the Std-ICE 
arm were treated with thoracic radiotherapy; 34 and 35, respec-
tively, were the responding patients with limited disease at baseline. 
Twenty-seven patients in each of the two study arms received PCI; 
20 and 21, respectively, had limited disease at baseline. Based on 
this selected group of patients, the overall response after thoracic 
radiotherapy was 40 of 44 (91%) in the High-ICE arm vs 39 of 48 
(81%) in the Std-ICE arm. 
 Progression-Free and Overall Survival 
 A total of 121 patients exhibited disease progression at the time 
of analysis, including 63 in the High-ICE arm vs 58 in the Std-
ICE arm. The first progression site was local in 29 (42%) vs 27 
patients (38%) and distant in 36 (52%) vs 30 patients (42%). 
Overall, sites of first distant progression included liver in 30 (28%), 
brain in 23 (21%), lung in 22 (20%), and bone in 9 (8%) of all 
patients, with many patients having disease progression at more 
than one site. 
 Median progression-free survival was 10.5 months overall (12.2 
months in the High-ICE arm vs 8.8 months in the Std-ICE arm; 
 P = .972) ( Figure 1 ). At 3 years, 9% (95% CI = 4% to 18%) and 
 Table 3 .  Nonhematologic toxicity in both arms of the trial * 
 Toxicity
High ICE (n = 158 cycles) Std ICE (n = 365 cycles) 
 WHO grade, No. WHO grade, No. 
 1 2 3 4 3/4, % 1 2 3 4 3/4, % 
 Ototoxicity  – 4 2  – 3  – 1  –  – 
 Mucosal 14 16 13 3 26 9 2 2  – 3 
 Nausea – vomiting 15 18 17 3 33 18 13 4  – 6 
 Gastrointestinal 12 16 12 4 26 10 4 1  – 1 
 Bleeding 10 7 5  – 8 6  – 1  – 1 
 Infections 3 10 15 4 31 1 10 3 1 6 
 Cardiac 2 4 3  – 5 1  – 1 2 4 
 Neurologic 7 6 2 3 8 8 2 2 1 4 
 Renal 3 11 4 1 8 3  –  – 1 1 
 *  High = high-dose; Std = standard-dose; ICE = ifosfamide, carboplatin, and etoposide; WHO = World Health Organization ( 24 );  – = none reported. Only patients 
who had any chemotherapy were considered, that is, n = 8 in the High-ICE arm and n = 1 in the Std-ICE arm were excluded. 
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15% (95% CI = 8% to 25%) of patients in the High-ICE and Std-
ICE arms, respectively, had not developed disease progression. 
 A total of 114 deaths were reported, including 58 and 56 patients 
in the High- and Std-ICE arms, respectively. The deaths were due 
to tumor progression in 45 and 43 patients, respectively, and to 
toxicity in 10 and 5 patients, respectively; other or unreported 
causes of death accounted for three and eight deaths, respectively. 
 Log-rank testing on the accumulated data yielded a statistic 
with a value of .09 ( P = .767), which was well within the stopping 
range of   0.500 to 0.500. Thus, no evidence for a potential treat-
ment effect was present. Three-year overall survival rates were 
18% (95% CI = 10% to 29%) in the High-ICE arm vs 19% (95% 
CI = 11% to 30%) in the Std-ICE arm. Overall median survival 
was 17.3 months (18.1 months in the High-ICE arm vs 14.4 
months in the Std-ICE arm;  Figure 2 ). 
 Exploratory analysis by disease extension, limited disease level, 
sex, and performance status did not suggest a beneﬁ t of High-ICE. 
In particular, the 2-year survival rate was 39% (95% CI = 25% to 
53%) vs 37% (95% CI = 23% to 50%) in the High-ICE vs Std-
ICE arms, respectively, when analyses were restricted to patients 
with limited disease. 
 Discussion 
 This study is the first, to our knowledge, to test in a randomized 
fashion the role of early intensification of chemotherapy adminis-
tered repeatedly with sequential courses supported by hematopoi-
etic stem cells for the treatment of SCLC. The EBMT designed 
the present trial to include a standard-dose arm as one of the most 
effective regimens available and a high-dose arm that would offer 
the maximum dose intensity. The trial was designed prospectively 
to test the hypothesis that increasing the dose intensity of the ICE 
regimen by a factor of three would double the long-term 3-year 
survival. Such a level of dose intensification has never been tested 
previously, but despite good compliance to the treatment plan, this 
therapeutic strategy failed to overcome the intrinsic chemoresis-
tance of SCLC. Such a level of chemotherapy dose intensification 
has been continuously advocated in the past until very recently, and 
it has subjected patients to clinically significant toxicities without 
creating a basis for solid conclusions ( 34 – 37 ); with the results of this 
study, this strategy should now be discarded. 
 The study was limited by its slow accrual rate. The decreasing 
incidence of SCLC in western Europe ( 2 ) and the fading interest 
in intensiﬁ cation for the treatment of solid tumors ( 38 , 39 ) had a 
negative impact on the accrual rate. To overcome this limitation, 
the EBMT was forced to modify the statistical design by introduc-
ing points of interim analysis with strong boundaries to draw solid 
deﬁ nitive conclusions. The present trial showed no differences 
between the High- and Std-ICE arms. Similar rates of overall 
(78% vs 68%) and complete (39% vs 34%) response were obtained. 
These results are in accord with those of our previous trial ( 23 ) and 
with other early intensiﬁ cation regimens in small phase II studies 
( 23 , 34 ). Also, the proportion of complete responders in the Std-
ICE arm was consistent with rates of 39% – 54% that have been 
documented for other Std-ICE regimens ( 15 , 40 ). 
 Progression-free survival was 12.2 months in the High-ICE arm 
and 8.8 months in the Std-ICE arm ( P = .972). Similar values, rang-
ing from 8.5 to 10.9 months, have been obtained with the dose-
densiﬁ cation approach, in which the increase in the dose intensity 
is obtained by reducing the interval between cycles without increas-
ing the dose per cycle ( 28 , 41 , 42 ). Sites of disease progression were 
similar in both treatment arms, with the brain being affected ﬁ rst in 
20% of patients. PCI and thoracic radiotherapy were delivered at 
the end of treatment to 42% and 71%, respectively, of patients with 
limited disease. It has been proposed that the rate of brain metasta-
ses can be reduced by early concomitant radiotherapy ( 43 ) and that 
the effect of radiotherapy on tumor control and ultimately on sur-
vival depends on the timing of radiotherapy, time to completion, 
dose, and fractionation schedule ( 44 – 46 ). Our radiotherapy sched-
ule was designed at a time when these issues were not settled. 
  
 Figure 1 .  Progression-free survival among patients in the trial. Kaplan –
 Meier analyses of progression-free survival.  Vertical lines are censored 
observations.  P = .972 (two-sided) was calculated using the log-rank 
test. High -ICE = high-dose chemotherapy with ifosfamide, carboplatin, 
and etoposide; Std-ICE = standard-dose chemotherapy with ifosfamide, 
carboplatin, and etoposide. 
  
 Figure 2 .  Overall survival among patients in the trial. Kaplan – Meier 
analyses of progression-free survival.  Vertical lines are censored obser-
vations.  P = .767 (two-sided) was calculated using the log-rank test. 
High-ICE = high-dose chemotherapy with ifosfamide, carboplatin, and 
etoposide; Std-ICE = standard-dose chemotherapy with ifosfamide, 
carboplatin, and etoposide. 
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 The primary endpoint of our study was 3-year overall survival, 
which was attained by 18% of patients in the High-ICE arm vs 
19% in the Std-ICE arm. Median overall survival was 18.1 vs 14.4 
months ( P = .767), with no advantage of High-ICE in any sub-
group analyses. Patients with limited disease showed 2-year sur-
vival rates of 39% vs 37%. These rates are consistent with the most 
active treatment strategies and a strategy combining minimal 
increase of chemotherapy with early radiotherapy (43%) ( 47 ) or 
concomitant chemotherapy with bifractionated radiotherapy (47%) 
( 48 ). Median 2-year survival values from 20% to 33% were 
obtained in dose-dense arms of various randomized trials ( 15 , 40 , 41 ). 
Our results are similar to those obtained by doubling the dose 
intensity ( 15 , 40 , 41 ). It is, however, difﬁ cult to compare different 
studies in general due to different patient selection. 
 The combination of paclitaxel and epidoxorubicin was unable 
to improve the results of High-ICE treatment but was a good regi-
men for mobilizing PBPCs. Transfusion of PBPCs allowed the 
relative dose intensity of High-ICE to be maintained in 91% of 
cycles and the median dose intensity to be increased to almost 
300% compared with Std-ICE treatment. This dose intensity was 
similar to that reached in our previous EBMT phase II study ( 23 ) 
and higher than in any previous trial. Although the High-ICE 
regimen led to more severe toxicity, the Std-ICE regimen was still 
toxic, involving grade 3 and higher infection in 6% and toxic death 
rate in 4% of patients. Other triplet regimens based on ifosfamide 
are also complicated by toxic effects , with severe leukopenia in 
71% – 96% of patients, grade 3 and higher infection in 15% – 84%, 
and toxic death in 2% – 12% ( 15 , 16 , 28 , 40 , 42 ). In comparison, PE 
caused grade 3 and greater neutropenia in 47% – 85% of patients 
and toxic death in 5.5% of patients ( 16 , 49 ). Severe myelosuppres-
sion associated with High-ICE treatment was an expected ﬁ nding, 
and in this arm, we observed grade 3 and higher infection in 31% 
and toxic death in 8% of patients. Other severe toxicities in this 
group included diarrhea and abdominal pain (26%), mucositis 
(26%), renal failure (8%), and neurological events (8%). This pro-
ﬁ le is consistent with a previous EBMT trial ( 23 ). The densiﬁ ca-
tion strategy used elsewhere ( 28 ) for doubling dose intensity also 
caused severe leukopenia and thrombopenia in 94% of patients 
and anemia in 71% ( 28 , 42 ). However, in these trials, neutropenic 
sepsis and toxic death were conﬁ ned to 18% – 56% and 3% of 
patients, respectively. Toxicity was also observed in the PBPC 
mobilization phase of the present trial, with toxic death in 3% 
(n = 2) of patients, compared with the collection of PBPCs by the 
whole-blood technique of the dose-densiﬁ cation approach, for 
which no toxicity was recorded ( 28 ). 
 The concept of dose intensiﬁ cation has now been studied 
exhaustively. Higher total doses involving more cycles and longer 
treatment periods have not improved survival ( 50 ), although some 
progress has been made through moderate enhancements, such as 
escalating doses over a few cycles, reducing cycle intervals, or com-
bining more agents ( 40 , 47 , 49 , 51 – 54 ). Increases of chemotherapy 
dose intensity in SCLC clinical trials have only been able to raise 
dose by 30% – 70%. Doubling the relative dose intensity by densi-
ﬁ cation of chemotherapy could not improve the results ( 28 ). The 
approach explored in the present trial succeeded in raising the peak 
dose, total dose, and dose intensity of ICE by threefold but has 
clearly been ineffective and highly toxic. In addition, this regimen 
is costly. As a result, this strategy should be abandoned. Research 
should now focus on other treatment approaches. 
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